Jason Aryeh - Net Worth and Insider Trading

Jason Aryeh Net Worth

The estimated net worth of Jason Aryeh is at least $15 Million dollars as of 2024-11-13. Jason Aryeh is the Director of Ligand Pharmaceuticals Inc and owns about 123,822 shares of Ligand Pharmaceuticals Inc (LGND) stock worth over $15 Million. Jason Aryeh is the Director of Novelion Therapeutics Inc and owns about 392,733 shares of Novelion Therapeutics Inc (NVLNF) stock worth over $275,699. Jason Aryeh is also the See Explanation of Responses of Merrimack Pharmaceuticals Inc and owns about 3,802 shares of Merrimack Pharmaceuticals Inc (MACK) stock worth over $57,524. Besides these, Jason Aryeh also holds Myrexis Inc (MYRX) . Details can be seen in Jason Aryeh's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Jason Aryeh has not made any transactions after 2019-09-03 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

Transaction Summary of Jason Aryeh

Jason Aryeh Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Jason Aryeh owns 10 companies in total, including Ligand Pharmaceuticals Inc (LGND) , Merrimack Pharmaceuticals Inc (MACK) , and Old API Wind-down Ltd (ARLZQ) among others .

Click here to see the complete history of Jason Aryeh’s form 4 insider trades.

Insider Ownership Summary of Jason Aryeh

Ticker	Comapny	Transaction Date	Type of Owner
LGND	Ligand Pharmaceuticals Inc	2019-09-03	director
MACK	Merrimack Pharmaceuticals Inc	2019-07-16	10 percent owner & other: See Explanation of Responses
ARLZQ	Old API Wind-down Ltd	2017-05-19	director
		2017-05-15	director
		2017-01-08	director
		2012-06-18	director
		2006-10-18	other: See Remarks Below
		2022-04-21	director
		2023-01-26	director
		2023-07-20	director

Jason Aryeh Latest Holdings Summary

Jason Aryeh currently owns a total of 4 stocks. Among these stocks, Jason Aryeh owns 123,822 shares of Ligand Pharmaceuticals Inc (LGND) as of September 3, 2019, with a value of $15 Million and a weighting of 97.79%. Jason Aryeh owns 392,733 shares of Novelion Therapeutics Inc (NVLNF) as of May 15, 2017, with a value of $275,699 and a weighting of 1.8%. Jason Aryeh also owns 3,802 shares of Merrimack Pharmaceuticals Inc (MACK) as of July 16, 2019, with a value of $57,524 and a weighting of 0.38%. The other 1 stocks Myrexis Inc (MYRX) have a combined weighting of 0.03% among all his current holdings.

Latest Holdings of Jason Aryeh

Ticker	Comapny	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
LGND	Ligand Pharmaceuticals Inc	2019-09-03	123,822	120.74	14,950,268
NVLNF	Novelion Therapeutics Inc	2017-05-15	392,733	0.70	275,699
MACK	Merrimack Pharmaceuticals Inc	2019-07-16	3,802	15.13	57,524
MYRX	Myrexis Inc	2012-06-18	555,145	0.01	3,886

Holding Weightings of Jason Aryeh

Jason Aryeh Form 4 Trading Tracker

According to the SEC Form 4 filings, Jason Aryeh has made a total of 0 transactions in Ligand Pharmaceuticals Inc (LGND) over the past 5 years. The most-recent trade in Ligand Pharmaceuticals Inc is the acquisition of 750 shares on September 3, 2019, which cost Jason Aryeh around $65,258.

According to the SEC Form 4 filings, Jason Aryeh has made a total of 0 transactions in Novelion Therapeutics Inc (NVLNF) over the past 5 years. The most-recent trade in Novelion Therapeutics Inc is the acquisition of 361 shares on May 15, 2017, which cost Jason Aryeh around $3,231.

According to the SEC Form 4 filings, Jason Aryeh has made a total of 0 transactions in Merrimack Pharmaceuticals Inc (MACK) over the past 5 years. The most-recent trade in Merrimack Pharmaceuticals Inc is the acquisition of 302 shares on July 16, 2019, which cost Jason Aryeh around $1,643.

More details on Jason Aryeh's insider transactions can be found in the Insider Trading History of Jason Aryeh table.

Insider Trading History of Jason Aryeh

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Jason Aryeh Trading Performance

GuruFocus tracks the stock performance after each of Jason Aryeh's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Jason Aryeh is 4.93%. GuruFocus also compares Jason Aryeh's trading performance to market benchmark return within the same time period. The performance of stocks bought by Jason Aryeh within 3 months outperforms 21 times out of 37 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Jason Aryeh's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Jason Aryeh

Average Return

Average return per transaction

Outperforming Transactions

21 out of 37 outperforming transactions.

Each transaction is measured over a period and compared to .

	1 Month	3 Months	6 Months	1 Year	2 Years	3 Years
Return(%)	6.23
Relative Return to S&P 500(%)	4.57

Jason Aryeh Ownership Network

Ownership Network List of Jason Aryeh

No Data

Ownership Network Relation of Jason Aryeh

Jason Aryeh Owned Company Details

What does Ligand Pharmaceuticals Inc do?

Who are the key executives at Ligand Pharmaceuticals Inc?

Jason Aryeh is the director of Ligand Pharmaceuticals Inc. Other key executives at Ligand Pharmaceuticals Inc include CHIEF LEGAL OFFICER & Andrew Reardon , VP & Finance and CFO Matthew E Korenberg , and Chief Financial Officer Octavio Espinoza .

Ligand Pharmaceuticals Inc (LGND) Insider Trades Summary

Over the past 18 months, Jason Aryeh made no insider transaction in Ligand Pharmaceuticals Inc (LGND). Other recent insider transactions involving Ligand Pharmaceuticals Inc (LGND) include a net sale of 70,748 shares made by Matthew E Korenberg , a net sale of 14,708 shares made by Octavio Espinoza , and a net sale of 13,500 shares made by Andrew Reardon .

In summary, during the past 3 months, insiders sold 39,680 shares of Ligand Pharmaceuticals Inc (LGND) in total and bought 0 shares, with a net sale of 39,680 shares. During the past 18 months, 106,227 shares of Ligand Pharmaceuticals Inc (LGND) were sold and 6,500 shares were bought by its insiders, resulting in a net sale of 99,727 shares.

Ligand Pharmaceuticals Inc (LGND)'s detailed insider trading history can be found in Insider Trading Tracker table.

Ligand Pharmaceuticals Inc Insider Transactions

No Available Data

What does Merrimack Pharmaceuticals Inc do?

Who are the key executives at Merrimack Pharmaceuticals Inc?

Jason Aryeh is the 10 percent owner & other: See Explanation of Responses of Merrimack Pharmaceuticals Inc. Other key executives at Merrimack Pharmaceuticals Inc include director & other: See Remarks Eric Andersen , director & President Gary L Crocker , and director & other: See Remarks Noah G. Levy .

Merrimack Pharmaceuticals Inc (MACK) Insider Trades Summary

Over the past 18 months, Jason Aryeh made no insider transaction in Merrimack Pharmaceuticals Inc (MACK). Other recent insider transactions involving Merrimack Pharmaceuticals Inc (MACK) include a net purchase of 446,418 shares made by Eric Andersen , and a net purchase of 4,000 shares made by Gary L Crocker .

In summary, during the past 3 months, insiders sold 0 shares of Merrimack Pharmaceuticals Inc (MACK) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Merrimack Pharmaceuticals Inc (MACK) were sold and 450,418 shares were bought by its insiders, resulting in a net purchase of 450,418 shares.

Merrimack Pharmaceuticals Inc (MACK)'s detailed insider trading history can be found in Insider Trading Tracker table.

Merrimack Pharmaceuticals Inc Insider Transactions

No Available Data

What does Old API Wind-down Ltd do?

Who are the key executives at Old API Wind-down Ltd?

Jason Aryeh is the director of Old API Wind-down Ltd. Other key executives at Old API Wind-down Ltd include President & Chief Business Off Andrew I Koven , Chief Medical Officer James Patrick Tursi , and Chief Commercial Officer Mark A Glickman .

Old API Wind-down Ltd (ARLZQ) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Old API Wind-down Ltd (ARLZQ) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Old API Wind-down Ltd (ARLZQ) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Old API Wind-down Ltd (ARLZQ)'s detailed insider trading history can be found in Insider Trading Tracker table.

Old API Wind-down Ltd Insider Transactions

No Available Data

What does Novelion Therapeutics Inc do?

Who are the key executives at Novelion Therapeutics Inc?

Jason Aryeh is the director of Novelion Therapeutics Inc. Other key executives at Novelion Therapeutics Inc include 10 percent owner Broadfin Healthcare Master Fund Ltd , 10 percent owner Broadfin Capital, Llc , and 10 percent owner Kevin Kotler .

Novelion Therapeutics Inc (NVLNF) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Novelion Therapeutics Inc (NVLNF) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Novelion Therapeutics Inc (NVLNF) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Novelion Therapeutics Inc (NVLNF)'s detailed insider trading history can be found in Insider Trading Tracker table.

Novelion Therapeutics Inc Insider Transactions

No Available Data

What does Immunomedics Inc do?

Who are the key executives at Immunomedics Inc?

Jason Aryeh is the director of Immunomedics Inc. Other key executives at Immunomedics Inc include director & 10 percent owner & other: See Remarks Venbio Select Advisor Llc , director & 10 percent owner & other: See Remarks Behzad Aghazadeh , and director & President and CEO Harout Semerjian .

Immunomedics Inc (IMMU) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Immunomedics Inc (IMMU) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Immunomedics Inc (IMMU) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Immunomedics Inc (IMMU)'s detailed insider trading history can be found in Insider Trading Tracker table.

Immunomedics Inc Insider Transactions

No Available Data

What does Myrexis Inc do?

Who are the key executives at Myrexis Inc?

Jason Aryeh is the director of Myrexis Inc. Other key executives at Myrexis Inc include 10 percent owner Xstelos Corp. , director & Chairman & President and CEO Jonathan Couchman , and 10 percent owner First Eagle Investment Management, Llc .

Myrexis Inc (MYRX) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Myrexis Inc (MYRX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Myrexis Inc (MYRX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Myrexis Inc (MYRX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Myrexis Inc Insider Transactions

No Available Data

What does Vaxart Inc do?

Who are the key executives at Vaxart Inc?

Jason Aryeh is the other: See Remarks Below of Vaxart Inc. Other key executives at Vaxart Inc include Chief Financial Officer Phillip E Lee , Interim CFO Fuad Ahmad , and SVP & General Counsel Edward B Berg .

Vaxart Inc (VXRT) Insider Trades Summary

Over the past 18 months, Jason Aryeh made no insider transaction in Vaxart Inc (VXRT). Other recent insider transactions involving Vaxart Inc (VXRT) include a net purchase of 20,000 shares made by W. Mark Watson ,

In summary, during the past 3 months, insiders sold 0 shares of Vaxart Inc (VXRT) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Vaxart Inc (VXRT) were sold and 20,000 shares were bought by its insiders, resulting in a net purchase of 20,000 shares.

Vaxart Inc (VXRT)'s detailed insider trading history can be found in Insider Trading Tracker table.

Vaxart Inc Insider Transactions

No Available Data

What does Anebulo Pharmaceuticals Inc do?

Who are the key executives at Anebulo Pharmaceuticals Inc?

Jason Aryeh is the director of Anebulo Pharmaceuticals Inc. Other key executives at Anebulo Pharmaceuticals Inc include director & Chief Executive Officer Richard Anthony Cunningham, , Chief Financial Officer Dan George , and Acting Chief Financial Officer Sandra A. Gardiner .

Anebulo Pharmaceuticals Inc (ANEB) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Anebulo Pharmaceuticals Inc (ANEB) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Anebulo Pharmaceuticals Inc (ANEB) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Anebulo Pharmaceuticals Inc (ANEB)'s detailed insider trading history can be found in Insider Trading Tracker table.

Anebulo Pharmaceuticals Inc Insider Transactions

No Available Data

What does Health Sciences Acquisitions Corp 2 do?

Who are the key executives at Health Sciences Acquisitions Corp 2?

Jason Aryeh is the director of Health Sciences Acquisitions Corp 2. Other key executives at Health Sciences Acquisitions Corp 2 include director & See Remarks David P Hochman , Chief Financial Officer Michael Kaswan , and director & See Remarks Darren Sherman .

Health Sciences Acquisitions Corp 2 (HSAQ) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Health Sciences Acquisitions Corp 2 (HSAQ) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Health Sciences Acquisitions Corp 2 (HSAQ) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Health Sciences Acquisitions Corp 2 (HSAQ)'s detailed insider trading history can be found in Insider Trading Tracker table.

Health Sciences Acquisitions Corp 2 Insider Transactions

No Available Data

What does Orchestra BioMed Holdings Inc do?

Who are the key executives at Orchestra BioMed Holdings Inc?

Jason Aryeh is the director of Orchestra BioMed Holdings Inc. Other key executives at Orchestra BioMed Holdings Inc include director & See Remarks David P Hochman , director & See Remarks Darren Sherman , and See Remarks William Reed Little .

Orchestra BioMed Holdings Inc (OBIO) Insider Trades Summary

Over the past 18 months, Jason Aryeh made no insider transaction in Orchestra BioMed Holdings Inc (OBIO). Other recent insider transactions involving Orchestra BioMed Holdings Inc (OBIO) include a net purchase of 18,500 shares made by David P Hochman , a net sale of 34,325 shares made by Darren Sherman , and a net sale of 5,600 shares made by Eric S Fain .

In summary, during the past 3 months, insiders sold 39,925 shares of Orchestra BioMed Holdings Inc (OBIO) in total and bought 12,500 shares, with a net sale of 27,425 shares. During the past 18 months, 39,925 shares of Orchestra BioMed Holdings Inc (OBIO) were sold and 22,500 shares were bought by its insiders, resulting in a net sale of 17,425 shares.

Orchestra BioMed Holdings Inc (OBIO)'s detailed insider trading history can be found in Insider Trading Tracker table.

Orchestra BioMed Holdings Inc Insider Transactions

No Available Data

Jason Aryeh Mailing Address

Above is the net worth, insider trading, and ownership report for Jason Aryeh. You might contact Jason Aryeh via mailing address: 11119 North Torrey Pines Road, Suite 200, La Jolla Ca 92037.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.